Trimas’ Q2 2026 Call: Beauty Demand Outlook and Food & Beverage Sales Causes Clash

Date of Call: Jul 30, 2026

Financials Results

• Revenue: $174.6M, up 1.6% YOY; Organic sales essentially flat
• EPS: $0.52 adjusted earnings per share, compared to $0.20 in the prior year period
• Operating Margin: 8.5%, expanded 180 basis points YOY

Guidance:

• Full-year sales growth expected to be 3% to 6%.
• Operating profit margin expected to improve by more than 300 basis points compared to 2025.
• Adjusted EPS guidance raised to $1.60 to $1.70 per share (lower end increased by 10 cents).
• Expect sequential margin expansion in Q3.
• Packaging full-year sales growth expected 3% to 6%; operating margin 14% to 15%.
• Specialty products full-year sales growth expected 6% to 9%; operating margin 6% to 8%.
• Expect improvement in sales, earnings, and adjusted EPS each quarter of 2026 YOY.

Business Commentary:

Revenue and Profitability Growth:

• Trimax Corporation reported net sales of $174.6 million for Q2 2026, a 1.6% year-over-year increase, with organic sales essentially flat.
• Operating profit increased 29% to $14.9 million, and adjusted earnings per share rose to 52 cents from 20 cents in the prior year period.
• The growth in profitability was driven by cost reduction initiatives, improved operational efficiency, and benefits from share repurchases.

Packaging Segment Performance:

• Packaging net sales were $143 million, essentially flat year-over-year, with a 3.7% increase in operating profit and a 50 basis points expansion in operating margin to 14.8%.
• The segment's performance was supported by cost reduction actions, operational excellence programs, and favorable foreign currency translation.

Specialty Products Segment Challenges:

• Specialty products segment reported a 10.2% year-over-year increase in net sales to nearly $32 million, but operating profit declined to $0.7 million from $1.3 million, with a margin drop to 2.2%.
• The decline in profitability was due to challenges in ramping up staffing and throughput to meet customer demand, leading to higher temporary labor and overhead costs.

Capital Allocation and Share Repurchases:

• Trimax has repurchased more than 5 million shares, reducing the share count to approximately 35.9 million shares outstanding, with $175 million spent on repurchases since November 2025.
• The share repurchases are part of a disciplined capital allocation strategy aimed at enhancing shareholder value and are viewed as a high-return action when no significant M&A opportunities are imminent.

Sentiment Analysis:

Overall Tone: Positive

• We delivered another quarter of solid execution, highlighted by continued profitability improvement and strong earnings growth... We are encouraged by our first-half performance... we believe TriMass is well-positioned to continue building momentum... we remain confident in our ability to continue building a stronger TriMass.

Q&A:

• Question from Zach Sherman (KeyBank Capital Markets): Is there an expectation for beauty and personal care or food and beverage to ramp back up in the second half? Any additional color on what drove the soft demand of packaging?
  Response: Softness in food & beverage was due to a one-time asset consolidation pause; demand is good and expected to recover. Beauty & personal care is anticipated to return to a normal pattern in the back half.

• Question from Zach Sherman (KeyBank Capital Markets): Could you help us understand other characteristics you would be looking at for potential M&A deals in life sciences?
  Response: Looking for higher-quality companies that elevate products, geography, positioning, and customer relationships, strengthen IP, and are not just margin-driven. Actively evaluating a pipeline with a disciplined lens.

• Question from Zach Sherman (KeyBank Capital Markets): In the absence of a deal, is there a potential opportunity to accelerate share repurchases?
  Response: Prioritize organic growth investments first; otherwise, maintain a balanced disciplined approach between M&A, share repurchases (with $76M remaining under current authorization), and capital returns.

• Question from Hamed Khorasan (BWS Financial): Could you just talk about your expectation on the packaging side regarding growth and how you're seeing that develop?
  Response: Growth is expected to come from organic market share gains and customer engagement improvements, not just currency benefits. Expect recovery in previously soft end markets like food & beverage.

• Question from Ken Newman (KeyBank Capital Markets): Could you give us a sense of how you are going to sequence additional internal improvement opportunities and when we could expect any sort of benefits?
  Response: More cost reduction and operational excellence actions are planned for H2, adding to the existing $10.5M (2026) and $16M (run rate) initiatives, with automation and modernization opportunities ahead.

Contradiction Point 1

Beauty & Personal Care Demand Outlook

It involves differing visibility and certainty regarding the demand recovery for the beauty/personal care segment, impacting expectations for future business performance.

Is Zach Sherman substituting for Ken Newman (KeyBank Capital Markets) in the earnings call? - Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken

2026Q2: Beauty and personal care demand is expected to return to a more normal, upturn pattern in the back half of the year, similar to Q1. - [Thomas Snyder](CEO)

What are the expectations for beauty/personal care and food/beverage sectors in H2, the visibility on project timing to avoid missing opportunities this quarter, and the factors driving soft demand in packaging? - Zach Sherman (KeyBanc Capital Markets)

2026Q2: For beauty and personal care, the business is expected to return to a more normal pattern in the back half of the year, with visibility indicating a positive outlook. - [Thomas Snyder](CEO)

Contradiction Point 2

Characterization of Q2 Food & Beverage Sales Issue

It involves different explanations for the cause of Q2 sales softness in food & beverage, affecting the understanding of underlying business performance.

Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken - Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken

2026Q2: The soft demand in food and beverage in Q2 was largely due to a one-time issue with the consolidation of the Atkins facility, which caused a temporary pause in sales as assets were relocated. - [Thomas Snyder](CEO)

Can you provide additional color on the soft demand in packaging, expectations for beauty/personal care and food/beverage industries in H2, and visibility on project timing to avoid losing projects this quarter? - Zach Sherman (KeyBanc Capital Markets)

2026Q2: For food and beverage, the Q2 sales issue was a one-time pause due to the consolidation of the Atkins facility, which has now been completed. - [Thomas Snyder](CEO)

Contradiction Point 3

Margin Expectations and Cadence

It involves changes in guidance on margin progression through the year, which is essential for financial planning and investor expectations.

Katie Fleischer (KeyBanc Capital Markets) - Katie Fleischer (KeyBanc Capital Markets)

2026Q2: The company is confident in achieving the stated margin improvements. - [Paul Swart](CFO)

What is the expected cadence of improvement in the Packaging segment this year, considering cost savings from facility consolidation and mix impacts? - Hamed Khorasan (BWS Financial)

2026Q1: Q1 is expected to be the lowest margin quarter. Margins are expected to increase sequentially through Q2 and Q3, with Q4 naturally falling back, but overall aligning with full-year guidance. - [Paul Swart](CFO)

Contradiction Point 4

Nature of Demand/Revenue Pressures

It involves a significant difference in characterizing the cause of Q2 revenue weakness, shifting from a one-time operational issue to an unforeseen, low-margin event.

Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken: - Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken:

2026Q2: The soft demand in food and beverage in Q2 was largely due to a one-time issue with the consolidation of the Atkins facility, which caused a temporary pause in sales as assets were relocated. - [Thomas Snyder](CEO)

Can you provide insight into expectations for beauty/personal care and food/beverage sectors, visibility on project timing to avoid missing projects this quarter, and the factors driving the soft demand in packaging? - Katie Fleischer (KeyBanc Capital Markets)

2026Q1: Q1 margins were pressured by a nearly $5 million tooling sale at a low margin for a program with production later in the year or early next year. This sale was not inherent in the Q1 forecast. - [Paul Swart](CFO) and [Thomas Snyder](CEO)

Contradiction Point 5

Capital Deployment and M&A Strategy Readiness

It involves a contradiction on specificity and readiness to discuss capital deployment plans, affecting strategic clarity for investors.

Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken - Ken Newman (KeyBank Capital Markets) – Zach Sherman on for Ken

2026Q2: The pipeline is active, but no specific timing or details can be shared. - [Paul Ford](CFO)

What key characteristics, such as deal size, margin profile, and speed of execution, do you consider for potential life sciences M&A? - Kenneth Newman (KeyBanc Capital Markets Inc.)

2025Q4: More specifics on capital deployment, including share buybacks and potential acquisitions, will be provided on the Q1 2026 earnings call after the deal closes. - [Thomas Snyder](CEO)